MannKind Corporation
Inhalable dry powder pharmaceutical composition

Last updated:

Abstract:

A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system.

Status:
Grant
Type:

Utility

Filling date:

19 Dec 2019

Issue date:

19 Apr 2022